EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Expert Consensus Recommendations for Optimized Diabetes Care: Dapagliflozin and Sitagliptin Fixed-dose Combination in Indian Clinical Practice

Ambika G. Unnikrishnan, Ragini Bhake, Rakesh Kumar Sahay, Subhash Chandra, Jabir Abdullakutty, Ashu Rastogi, Anish Behl, Kamal H. Sharma, Om J. Lakhani, Pankaj Sarkar, Rohan Kesarkar, Ashish Prasad und 1 weitere

Chronicle of Diabetes Research and Practice · 2025

DOI: 10.4103/cdrp.cdrp_11_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chronicle of Diabetes Research and Practice, 2025. Verfasst von Ambika G. Unnikrishnan und 12 weiteren Autor:innen. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The fixed-dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors offers an effective, non-metformin based option for patients with type-2 diabetes mellitus (T2DM) who cannot tolerate metformin. The objective of the study was to address the existing gaps in knowledge about FDC of SGLT-2 inhibitors and DPP-4 inhibitors particularly, the combination of dapagliflozin and sitagliptin FDC and to provide evidence to address these issues.

Methods

This cross-sectional, observational, questionnaire-based study was conducted at five round table meetings, which included clinicians from India. A validated questionnaire (of 9 questions) was used to assess clinical views on dapagliflozin and sitagliptin FDC therapy for T2DM management. The opinions and suggestions from all the meetings were compiled and analyzed, to derive the consensus statement.

Results

A strong consensus (89.47%) identified efficacy as the key factor for the early initiation of combination therapies for glycemic control. Experts (90.91%) agreed that combining SGLT-2 inhibitors and DPP-4 inhibitors enhances insulin sensitivity. A consensus (55.56%) supported early initiation of dapagliflozin and sitagliptin FDC to reduce hypoglycemia risk. Experts also noted the regimen’s simplicity (59.26%) and, with a majority (78.57%), agreed that it reduces major cardiovascular (CV) events, weight, blood pressure, and heart failure risk while improving the lipid profile. Most experts (80.56%) supported the early use of dapagliflozin and sitagliptin FDC in T2DM patients with CV risk.

Conclusion

The consensus strongly indicates that early initiation of dapagliflozin and sitagliptin FDC therapy improves glycemic control, reduces CV events, and enhances patient outcomes.

Zitieren

APA

Unnikrishnan, A. G., Bhake, R., Sahay, R. K., Chandra, S., Abdullakutty, J., Rastogi, A., Behl, A., Sharma, K. H., Lakhani, O. J., Sarkar, P., Kesarkar, R., Prasad, A., & Pednekar, A. (2025). Expert Consensus Recommendations for Optimized Diabetes Care: Dapagliflozin and Sitagliptin Fixed-dose Combination in Indian Clinical Practice. Chronicle of Diabetes Research and Practice. https://doi.org/10.4103/cdrp.cdrp_11_25

Vancouver

Unnikrishnan AG, Bhake R, Sahay RK, Chandra S, Abdullakutty J, Rastogi A, et al. Expert Consensus Recommendations for Optimized Diabetes Care: Dapagliflozin and Sitagliptin Fixed-dose Combination in Indian Clinical Practice. Chronicle of Diabetes Research and Practice. 2025. doi:10.4103/cdrp.cdrp_11_25

BibTeX
@article{Unnikrishnan2025,
  author = {Unnikrishnan, Ambika G. and Bhake, Ragini and Sahay, Rakesh Kumar and Chandra, Subhash and Abdullakutty, Jabir and Rastogi, Ashu and Behl, Anish and Sharma, Kamal H. and Lakhani, Om J. and Sarkar, Pankaj and Kesarkar, Rohan and Prasad, Ashish and Pednekar, Abhijit},
  title = {Expert Consensus Recommendations for Optimized Diabetes Care: Dapagliflozin and Sitagliptin Fixed-dose Combination in Indian Clinical Practice},
  journal = {Chronicle of Diabetes Research and Practice},
  year = {2025},
  doi = {10.4103/cdrp.cdrp_11_25}
}
Kostenlos starten →